Virological Response and HIV Drug Resistance 12 Months After Antiretroviral Therapy Initiation at 2 Clinics in Nigeria | Zendy

Richard Ugbena | Zendy; John AberleGrasse | Zendy; Karidia Diallo | Zendy; Okon Bassey | Zendy; Tapdiyel Jelpe | Zendy; Erin Rottinghaus | Zendy; Aderemi Azeez | Zendy; Richard Peter Akpan | Zendy; Mukhtar Muhammad | Zendy; Vedapuri Shanmugam | Zendy; Sheo Pratap Singh | Zendy; Chunfu Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Virological Response and HIV Drug Resistance 12 Months After Antiretroviral Therapy Initiation at 2 Clinics in Nigeria

Author(s) -

Richard Ugbena,

John AberleGrasse,

Karidia Diallo,

Okon Bassey,

Tapdiyel Jelpe,

Erin Rottinghaus,

Aderemi Azeez,

Richard Peter Akpan,

Mukhtar Muhammad,

Vedapuri Shanmugam,

Sheo Pratap Singh,

Chunfu Yang

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir1064

Subject(s) - medicine , antiretroviral therapy , hiv drug resistance , human immunodeficiency virus (hiv) , drug resistance , lost to follow up , first line , viral load , pediatrics , virology , microbiology and biotechnology , biology

This report describes a pilot study, conducted in Nigeria, of the World Health Organization protocol for monitoring human immunodeficiency virus (HIV) drug resistance (HIVDR) and associated program factors among patients receiving first-line antiretroviral therapy (ART). In 2008, 283 HIV-infected patients starting ART were consecutively enrolled at 2 ART clinics in Abuja. Twelve months after ART initiation, 62% were alive and on first-line ART, 3% had died, 1% had transferred out of the program, and 34% were lost to follow-up. Among patients on first-line ART at 12 months, 90% had viral suppression. However, in view of the high loss to follow-up rate (34%), strategies for patient retention and tracking are critical to minimize possible HIVDR and optimize treatment outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research